Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 3 3Phase 1 2Phase 2/3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Renal Insufficiency 1Neoplasms 1Liver Diseases 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Interventional × rubitecan × Clear all
NCT00113113 2024-08-02

Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction

Astex Pharmaceuticals, Inc.

Phase 1 Completed
54 enrolled

Liver Diseases, Neoplasms, Renal Insufficiency

NCT00006047 2012-09-26

Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
44 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡